CD274 and neoplasm: The reported rate of PD-L1 expression in the different tumors is endowed with a high variability across studies, and, considering specifically the neoplastic diseases with enhanced response to ICIs, namely NSCLC, melanoma and RCC, it ranges between 14 and 100% (21).